Orchestra BioMed Holdings, Inc.
OBIO
$4.03
$0.082.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -87.33% | 12,120.16% | -12.77% | 7.46% | 40.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -87.33% | 12,120.16% | -12.77% | 7.46% | 40.00% |
| Cost of Revenue | -27.27% | -12.07% | -27.94% | 4.55% | 29.41% |
| Gross Profit | -90.53% | 15,728.72% | -11.64% | 7.63% | 40.61% |
| SG&A Expenses | 1.76% | 23.52% | 25.27% | -3.14% | 6.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.11% | 42.72% | 22.19% | 14.32% | 31.55% |
| Operating Income | -16.67% | 140.50% | -24.30% | -14.64% | -31.19% |
| Income Before Tax | -10.32% | 138.66% | -35.02% | -21.17% | -39.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.32% | 138.66% | -35.02% | -21.17% | -39.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.32% | 138.66% | -35.02% | -21.17% | -39.31% |
| EBIT | -16.67% | 140.50% | -24.30% | -14.64% | -31.19% |
| EBITDA | -16.71% | 141.20% | -24.38% | -14.66% | -31.28% |
| EPS Basic | 32.74% | 122.79% | 2.66% | -12.97% | -30.35% |
| Normalized Basic EPS | 25.47% | 123.75% | 2.69% | -13.14% | -30.80% |
| EPS Diluted | 32.74% | 122.79% | 2.66% | -12.97% | -30.35% |
| Normalized Diluted EPS | 25.47% | 123.75% | 2.69% | -13.14% | -30.80% |
| Average Basic Shares Outstanding | 64.04% | 62.80% | 38.71% | 7.24% | 6.87% |
| Average Diluted Shares Outstanding | 64.04% | 62.80% | 38.71% | 7.24% | 6.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |